A study assessing COVID-HIG for the treatment for severe hospitalized patients as well as protection for at-risk individuals
Latest Information Update: 06 Apr 2020
At a glance
- Drugs COVID-2019 immune globulins (Human) (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 02 Apr 2020 According to an Emergent BioSolutions media release, company and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have agreed to incorporate the company COVID-HIG product candidate into one of NIAID clinical studies for assessment of treatments for COVID-19 once clinical material is available, and the study begins.
- 26 Mar 2020 New trial record
- 11 Mar 2020 According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020.
Most Recent Events
Trial Overview
Purpose
This study will be evaluating COVID-HIG for the treatment for severe hospitalized patients as well as protection for at-risk individuals.
Diseases Treated
Indication | Qualifiers | Patient Segments |
---|---|---|
COVID 2019 infections | prevention | - |
Subjects
- Subject Type patients
- Sex male & female
- Age Group adult
Trial Details
Organisations
- Affiliations Emergent BioSolutions
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase II
- Location Unknown
- Focus Therapeutic Use
Interventions
Drugs | Route | Formulation |
---|---|---|
COVID-2019 immune globulins (Human)Primary Drug | Intravenous | Infusion |
COVID-HIG
Trial History
Event Date | Event Type | Comment |
---|---|---|
02 Apr 2020 | Other trial event | According to an Emergent BioSolutions media release, company and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), have agreed to incorporate the company COVID-HIG product candidate into one of NIAID clinical studies for assessment of treatments for COVID-19 once clinical material is available, and the study begins. Updated 06 Apr 2020 |
26 Mar 2020 | New trial record | New trial record Updated 26 Mar 2020 |
11 Mar 2020 | Other trial event | According to an Emergent BioSolutions media release, this study is expected to begin as early as the third quarter of 2020. Updated 26 Mar 2020 |
References
-
Emergent BioSolutions. Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease. Media-Rel 2020;.
Media Release -
Emergent BioSolutions. Emergent BioSolutions Partners with U.S. Government for Comprehensive Response to Expedite Development of Plasma-Derived Therapy for COVID-19. Media-Rel 2020;.
Media Release -
Emergent BioSolutions. Emergent BioSolutions Joins U.S. Governments Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG